Studies related to Blood Pressure and Lactobacillus reuteri

Evaluation Of Clinical Safety And Tolerance Of A Lactobacillus Reuteri NCIMB 30242 Supplement Capsule: A Randomized Control Trial

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 124
Gender Both Genders
Age Range 30-44, 45-64
Body Types Overweight
Notes for this study:
Supplementation of _l. reuteri_ NCIMB 30242 at 2.9x10^9^ CFU twice daily in otherwise healthy hypercholesteromic adults for nine weeks did not appear to confer any significant toxic effects relative to placebo.

LDL cholesterol appeared to be reduced 11.7% with supplementation, but most other parameters were unchanged.
Funding issues for this study:
Funding provided by Micropharma, producer of Cardioviva

Full details on all 2 studies are available to Examine Plus members.